Custom Antibody Market– Forecast (2025-2031 - Forecast(2025 - 2031)

Overview

The Custom Antibody market size is forecast to reach USD 936.2 million by 2031, after growing at a CAGR of 8.53% during the forecast period 2025-2031. The custom antibody market is a growing industry that involves developing, producing, and purifying antibodies for use in various research applications. The market includes raw material suppliers, service providers, regulatory authorities, applications, and end users, such as pharmaceutical and biotechnology companies, academic and research institutes, and contract research organizations. To satisfy the needs of every host, custom antibodies can be produced in hamsters, rabbits, and mice. A variety of antibodies are offered by companies based on the needs of researchers. The custom antibody market is expanding rapidly due to the increasing demand for personalized medicine, the rise in chronic diseases, and the ongoing need for novel treatments and diagnostics. 

Report Coverage

The report “Custom Antibody Market– Forecast (2025-2031)”, by IndustryARC, covers an in-depth analysis of the following segments of Custom Antibody.

By  Type: Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Antibodies, and Others

By Service: Antibody Development, Antigen Preparation, Antibody Characterization, Immunization and Hybridoma Production, Antibody Production and Purification, Antibody Fragmentation and Labeling

By Source: Mice, Rabbits, Others

By Research Area: Immunology, Neurobiology, Oncology, Infectious Diseases, Cardiovascular Diseases, and Others

By Application: Therapeutics, Research

By End Users: Pharmaceutical and Biotechnology Companies, Contract Research Organizations, Research and Academic Institutions

By Geography:  North America, South America, Europe, APAC, Middle East & Africa

Key Takeaways

•    The Horizon Europe program of the European Union has allocated over €95.5 billion for research and innovation projects spanning from 2021 to 2027, which will greatly assist antibody research endeavors. Such strong funding channels, according to a report by the Global Health Institute, are crucial in hastening the discovery and development of novel antibody therapeutics, underscoring the critical role that government funding plays in promoting healthcare technologies and research.

•    In October 2022, The FcResolv NOG portfolio, an immunodeficient mouse model devoid of murine Fc gamma receptors, was released, according to Taconic Biosciences. According to the business, this will help advance antibody-based medicinal methods in the preclinical stage for the custom antibody sector by allowing scientists to assess possible candidates without interfering with residual murine Fc gamma receptor activation.

•    In October 2023, Sino Biological launched its new Center for Bioprocessing (C4B) in Houston, Texas, to be formally open. The launch represents a critical turning point in the business's international growth. The facility focuses on providing contract research services, which include creating and producing unique recombinant proteins and antibodies. The group is keen to collaborate with scientists and business titans globally to create a more promising future for the life sciences, and they are dedicated to producing top-notch products.

By Type - Segment Analysis

Monoclonal Antibodies led the market with a 68.5% market share in 2024. By inhibiting specific cell receptors, monoclonal antibodies strengthen the patient's immune system and stave off illness. Only one patient produced these antibodies. They are widely used in pre-clinical research, both in vivo and in vitro. Research institutes and pharmaceutical businesses can now access custom monoclonal antibody production services from a wide range of biotechnology companies.

For instance, in 2020, A novel recombinant monoclonal antibody development service for mice and rabbits, powered by an innovative technology platform, was introduced by AMSBIO. The ability of the DimAbTM development platform to directly separate IgG genes from B cells of inoculated animals sets it apart from conventional hybridoma fusion technologies. Numerous custom development projects have already been finished with excellent client satisfaction using this innovative platform.

By Service - Segment Analysis

Antibody Production and Purification occupied a dominant position in the Custom Antibody market in 2024. Custom antibody synthesis is a very useful technique when one has to create an antibody against a rare or specific antigen. The procedure is particularly useful for manufacturing monoclonal antibodies, as it allows one to store a hybridoma cell line used to generate an antibody for later use. Other members of the scientific community can also profit from this technique. Common techniques for purifying IgM antibodies for use in commercial-scale operations include gel filtration, ammonium sulphate precipitation, zone electrophoresis, and ion exchange chromatography. Protein A or G removal of IgG and ammonium sulphate precipitation are two basic enrichment methods for blood samples (polyclonal).

The majority of researchers choose to use antibody production and purification when creating antibodies against peptides. This procedure eliminates undesirable pre-immune antibodies while maximizing the isolation and enrichment of only the most specific antibodies produced against the antigen. Because antibodies may be used at larger concentrations (lower dilutions) without increasing signal background, this technique is advantageous for many applications, including IHC and IF.

By Source-Segment Analysis

Mice accounted for the largest share of the market in 2024. The most common hosts for producing antibodies for use in research are mice. Because of their small size, mice are easier to maintain and handle than other experimental sources and have reduced feeding expenditures. They generate antibody isotypes (IgA, IgE, IgD, IgG, and IgM) that resemble humans. Furthermore, a strong immune response can be elicited in laboratory mice against a variety of antigens, including highly similar human proteins. Furthermore, some drugs that are prohibited for human use can be used lawfully on mice and produce outcomes that are similar to those of humans. Due to the pharmaceutical industry's quick manufacture of therapeutic antibodies, mice have previously been crucial in the discovery and pre-clinical evaluation of monoclonal antibodies.
For instance, in October 2022, The FcResolv NOG portfolio, a model of immunodeficient mice devoid of murine Fc gamma receptors, was released by Taconic Biosciences, according to the company, the product is expected to support antibody-based therapeutic methods at the preclinical stage for the Custom Antibody antibody market by allowing scientists to assess possible candidates without interfering with residual murine Fc gamma receptor activity.

By Research Area – Segment Analysis

Immunology occupied a dominant position in the Custom Antibody market in 2024. Custom antibodies are used in a variety of immunology research tasks, including immune cell population identification and characterization, cytokine and other signaling molecule detection, and immune response analysis to infections or therapeutic interventions. Additionally, they play a critical role in the creation and validation of therapeutic approaches and diagnostic assays, especially in the context of personalized medicine and emerging diseases. Custom antibodies made to meet specific research demands are projected to become increasingly in demand as immunology remains a major focus of biomedical research, particularly with the growing interest in immunotherapies and vaccine development.

For instance, on 22 July 2024, Scientists at the University of Southern California (USC) discovered a way to reprogram B cells' immunoglobulin locus so that they can generate specifically engineered antibodies—which aren't triggered by vaccination—that can kill HIV or cancer cells.

By End User – Segment Analysis

Pharmaceutical and Biotechnology Companies occupied a dominant position in the Custom Antibody market in 2024. Biotechnology and pharmaceutical companies are putting more and more effort into developing biologics, such as biosimilars, antibody-drug conjugates, and monoclonal antibodies. Because custom antibodies are made to specifically target antigens associated with a disease, they play a crucial role in these processes. This makes them suitable for developing targeted therapeutics, which are more effective and have fewer adverse effects than conventional small-molecule medications.

According to Germany Trade & Invest, Germany's pharmaceutical sector spent more than EUR 8.7 billion on research and development in 2021 compared to all other European nations. Of the major German businesses, the pharmaceutical industry has the highest research intensity (11.1 percent of revenues were reinvested in internal R&D projects in 2020, for a total of 16.5 percent research intensity).

By Geography - Segment Analysis

The North America region in the Custom Antibody market is anticipated to hold a major share with a CAGR of 7.9% during the forecast period (2025-2031).   Owing to the existence of large corporations, substantial government financing, and a rise in research activity. Comprehensive research initiatives in cancer and genetics are also carried out by universities in the US and Canada. Due to these causes, the biotechnology industry is developing more swiftly, which has raised the demand for high-throughput technological solutions in laboratory operations. Because of the quick uptake of cutting-edge technical solutions, significant R&D expenditures, and rising costs for skilled workers. 

According to the Information Technology & Innovation Foundation, America is home to 85% of the world's small, research-intensive custom antibodies companies. The United States is a prominent market for custom antibodies due to ongoing investment and growth of asset base and production capabilities to meet the fast-growing demand for custom antibodies in the life sciences, personal care, and industrial applications. Furthermore, there have been increasing regulatory approvals for cell culture-based vaccines and substantial investments in cell-based research.

Drivers – Custom Antibody Market

•    Growing Demand for Personalized Medicine

The growing need for personalized medicine is driving the custom antibody market's explosive expansion. The area of personalized medicine is a recent development that focuses on tailoring medical interventions to the specific requirements of individual patients. The need for custom antibodies is being driven by this strategy, which creates individualized treatment programs by thoroughly examining the patient's genetic composition, medical history, and lifestyle. The process of creating custom antibodies involves first immunizing animals with the target antigen, and then separating and purifying the resultant antibody. These antibodies help in individualized disease diagnosis and treatment because they are made to specifically target a particular protein or antigen. The need for targeted medicines and the rising incidence of chronic illnesses like cancer are fueling the market for custom antibodies.

As per the 2020 research by the Personalized Medicine Coalition, there has been a surge in the quantity of personalized medicine medications, therapies, and diagnostic products since 2006. It is expected that this trend will persist in the upcoming years. Furthermore, during the previous five years, biopharmaceutical companies have nearly doubled their R&D investments in personalized medicine; during the next five years, this trend is expected to continue, with an additional 33 percent increase.

Treating cancer and other chronic diseases using customized medication has become increasingly widespread. Thus, the market is growing as a result of the growing use of custom antibodies. In June of 2021, for instance, GenScript unveiled MonoRab, a brand-new rabbit mAB. mAB sequencing and hybridoma are the technologies under question. Through a range of applications, it is more affine and has more specificity. Custom antibody market revenue is rising as a result of expanding public and private partnerships, growing government funding and support, changing disease profiles, and improvements in biotechnology research.

•    Growing Research Funding and Activities

The extended research and approval periods in the R&D sector have made the sector capital-intensive. Investment in R&D holds a prominent place in global spending. Governments understand that investing in research and development is essential to the advancement of the nation, its competitiveness in the global market, and the general welfare. Consequently, funding and spending for R&D have risen throughout time.

The significant investments by large pharmaceutical corporations in research and development, coupled with increased funding for genomic projects, are key drivers of the custom antibody market's expansion. For example, Pfizer's $43 billion investment to battle cancer in March 2023 underscores the growing emphasis on developing targeted therapies, which heavily rely on custom antibodies. As research activity intensifies and funding becomes more accessible, the demand for specialized antibodies tailored to specific research and therapeutic needs is expected to surge, further propelling the growth of the custom antibody market.

According to the Research America, in 2020, US medical and health research expenditures were $245.1 billion. health and medical research and development $161.8 billion in medical and health research was invested by the industry. $61.5 billion was invested by federal agencies and departments. $16.8 billion of the cash invested came from academic and research institutions. Professional societies, associations for voluntary health care, and foundations were offered. Funding for medical and health research and development totals $3 billion. States invested $2.1 billion in health research and development.

The market for custom antibodies is rising as a result of increased funding for life sciences research, particularly in the areas of proteomics, drug development, and genomics. These antibodies are essential research instruments that enable scientists to precisely target and study particular proteins.

Challenges – Custom Antibody Market

•    High-cost and Time-Consuming Antibody Development

The development and production of custom antibodies is time-consuming and expensive, especially when transgenic animals are involved. These limitations significantly limit the market's potential growth. The complicated steps and factors involved in developing antibodies through transgenic animals increase the process's total duration and expense. For example, compared to the synthesis of monoclonal or polyclonal antibodies, the preparation of recombinant antibodies, from antigen preparation to protein purification from cDNA, may be less expensive. However, using transgenic animals to produce monoclonal antibodies (mAbs) involves significant financial outlays for everything from antigen preparation to mAb purification using affinity chromatography. The process of producing hybridomas is made more expensive and logistically complex by its reliance on animals.

Market Landscape

In 2023, the top players in the Custom Antibody market share accounted for 67.0% of the share. Major players in the Custom Antibody market are Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., GenScript Biotech Corporation, BioLegend, Inc., Cell Signaling Technology, Inc., Sino Biological, Inc, and Others.

Developments:

•     In 2023, Danaher announced plans to spin off its Environmental and Applied Solutions business to create two independent companies, focusing more on its core life sciences and diagnostics markets, including custom antibodies.
•     Thermo Fisher acquired The Binding Site Group, which specializes in diagnostic instruments and reagents, further enhancing their diagnostic and custom antibody portfolio in 2022.

For more Lifesciences and Healthcare reports, please click here